Online inquiry

IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1612MR)

This product GTTS-WQ1612MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets GDF11 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005811.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10220
UniProt ID O95390
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1612MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2868MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ14043MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ15804MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ594MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ12978MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ10453MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ10472MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ13004MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW